1-苄基-3-溴-哌啶-4-酮氢溴酸 | 83877-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苄基-3-溴-哌啶-4-酮氢溴酸
• 中文别名: 1-苄基-3-溴-4-哌啶酮氢溴酸盐
• 英文名称: 3-bromo-1-(phenylmethyl)-4-piperidinone hydrobromide
• 英文别名: 1-benzyl-3-bromopiperidin-4-one hydrobromide；1-benzyl-3-bromopiperidin-4-one;hydrobromide
• CAS: 83877-88-7
• 化学式: BrH*C₁₂H₁₄BrNO
• 分子量: 349.065
• InChiKey: WAXUDOAUXCKKAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-苄基-3-溴-哌啶-4-酮氢溴酸 以55的产率得到4,4-二甲氧基-1-苯基-3-哌啶醇
  参考文献：
  名称：

  Drug Dev. Res. 1986, 8, 225-232

  摘要：

  DOI：
• 作为产物：
  描述：

  N-苄基哌啶酮 、 溴 生成 1-苄基-3-溴-哌啶-4-酮氢溴酸
  参考文献：
  名称：

  VAN DAELE G. H. P.; DE BRUYN M. F. L.; SOMMEN F. M.; JANSSEN M.; VAN NUET+, DRUG DEV. RES., 8,(1986) N 1-4, 225-232

  摘要：

  DOI：

文献信息

• Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors
  申请人：Netz Astrid

  公开号：US20070299074A1

  公开（公告）日：2007-12-27

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及通式I的胍化合物及其对应的对映异构体、顺反异构体和/或互变异构体，以及其药学上可接受的盐。本化合物进一步涉及胍化合物作为5-HT5受体的结合伴侣，用于治疗受5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
  申请人：Netz Astrid

  公开号：US20110237589A1

  公开（公告）日：2011-09-29

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及一般式I的胍化合物，其对应的对映异构体、顺反异构体和/或互变异构体以及其药学上可接受的盐。本化合物进一步涉及将胍化合物用作5-HT5受体的结合伴侣，用于治疗由5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0076530B1

  公开（公告）日：1985-12-11
• VAN DAELE G. H. P.; DE BRUYN M. F. L.; SOMMEN F. M.; JANSSEN M.; VAN NUET+, DRUG DEV. RES., 8,(1986) N 1-4, 225-232
  作者：VAN DAELE G. H. P.、 DE BRUYN M. F. L.、 SOMMEN F. M.、 JANSSEN M.、 VAN NUET+

  DOI：——

  日期：——
• GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
  申请人：ABBVIE DEUTSCHLAND GMBH & CO. KG

  公开号：US20170037016A1

  公开（公告）日：2017-02-09

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.